BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Garvin B, Wiley JW. The role of serotonin in irritable bowel syndrome: implications for management. Curr Gastroenterol Rep. 2008;10:363-368. [PMID: 18627647 DOI: 10.1007/s11894-008-0070-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 Wang YM, Chang Y, Chang YY, Cheng J, Li J, Wang T, Zhang QY, Liang DC, Sun B, Wang BM. Serotonin transporter gene promoter region polymorphisms and serotonin transporter expression in the colonic mucosa of irritable bowel syndrome patients. Neurogastroenterol Motil. 2012;24:560-565, e254-e255. [PMID: 22435794 DOI: 10.1111/j.1365-2982.2012.01902.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
2 Fichna J, Storr MA. Brain-Gut Interactions in IBS. Front Pharmacol. 2012;3:127. [PMID: 22783191 DOI: 10.3389/fphar.2012.00127] [Cited by in Crossref: 66] [Cited by in F6Publishing: 64] [Article Influence: 7.3] [Reference Citation Analysis]
3 Khalighi Sikaroudi M, Mokhtare M, Shidfar F, Janani L, Faghihi Kashani A, Masoodi M, Agah S, Dehnad A, Shidfar S. Effects of vitamin D3 supplementation on clinical symptoms, quality of life, serum serotonin (5-hydroxytryptamine), 5-hydroxy-indole acetic acid, and ratio of 5-HIAA/5-HT in patients with diarrhea-predominant irritable bowel syndrome: A randomized clinical trial. EXCLI J 2020;19:652-67. [PMID: 33013260 DOI: 10.17179/excli2020-2247] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
4 Akiho H, Ihara E, Nakamura K. Low-grade inflammation plays a pivotal role in gastrointestinal dysfunction in irritable bowel syndrome. World J Gastrointest Pathophysiol. 2010;1:97-105. [PMID: 21607147 DOI: 10.4291/wjgp.v1.i3.97.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Matsumoto S, Hashizume K, Wada N, Hori J, Tamaki G, Kita M, Iwata T, Kakizaki H. Relationship between overactive bladder and irritable bowel syndrome: a large-scale internet survey in Japan using the overactive bladder symptom score and Rome III criteria. BJU Int 2013;111:647-52. [PMID: 23106867 DOI: 10.1111/j.1464-410X.2012.11591.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 15] [Article Influence: 3.9] [Reference Citation Analysis]
6 Nau F Jr, Yu B, Martin D, Nichols CD. Serotonin 5-HT2A receptor activation blocks TNF-α mediated inflammation in vivo. PLoS One 2013;8:e75426. [PMID: 24098382 DOI: 10.1371/journal.pone.0075426] [Cited by in Crossref: 71] [Cited by in F6Publishing: 73] [Article Influence: 8.9] [Reference Citation Analysis]
7 Chey WD, Maneerattaporn M, Saad R. Pharmacologic and complementary and alternative medicine therapies for irritable bowel syndrome. Gut Liver 2011;5:253-66. [PMID: 21927652 DOI: 10.5009/gnl.2011.5.3.253] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 5.0] [Reference Citation Analysis]
8 Akiho H, Ihara E, Nakamura K. Low-grade inflammation plays a pivotal role in gastrointestinal dysfunction in irritable bowel syndrome. World J Gastrointest Pathophysiol 2010; 1(3): 97-105 [PMID: 21607147 DOI: 10.4291/wjgp.v1.i3.97] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 60] [Article Influence: 5.1] [Reference Citation Analysis]
9 Charnay Y, Léger L. Brain serotonergic circuitries. Dialogues Clin Neurosci 2010;12:471-87. [PMID: 21319493 [PMID: 21319493 DOI: 10.31887/dcns.2010.12.4/ycharnay] [Cited by in Crossref: 54] [Article Influence: 5.4] [Reference Citation Analysis]
10 Bolino CM, Bercik P. Pathogenic factors involved in the development of irritable bowel syndrome: focus on a microbial role. Infect Dis Clin North Am. 2010;24:961-975, ix. [PMID: 20937460 DOI: 10.1016/j.idc.2010.07.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
11 Li Z, Huang W, Wang X, Zhang Y. The relationship between lower urinary tract symptoms and irritable bowel syndrome: a meta-analysis of cross-sectional studies. Minerva Urol Nefrol 2018;70. [DOI: 10.23736/s0393-2249.18.03044-8] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Cheyette BNR, Cheyette SNR. Acute exacerbation of irritable bowel syndrome prevented by prn oral triptan. Clin J Gastroenterol 2016;9:375-8. [DOI: 10.1007/s12328-016-0689-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
13 Stasi C, Caserta A, Nisita C, Cortopassi S, Fani B, Salvadori S, Pancetti A, Bertani L, Gambaccini D, de Bortoli N, Dell'Osso L, Blandizzi C, Marchi S, Bellini M. The complex interplay between gastrointestinal and psychiatric symptoms in irritable bowel syndrome: A longitudinal assessment. J Gastroenterol Hepatol 2019;34:713-9. [PMID: 29971822 DOI: 10.1111/jgh.14375] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 7.3] [Reference Citation Analysis]
14 Fernández-Reina A, Urdiales JL, Sánchez-Jiménez F. What We Know and What We Need to Know about Aromatic and Cationic Biogenic Amines in the Gastrointestinal Tract. Foods 2018;7:E145. [PMID: 30181486 DOI: 10.3390/foods7090145] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
15 Friedrich M, Grady SE, Wall GC. Effects of antidepressants in patients with irritable bowel syndrome and comorbid depression. Clin Ther. 2010;32:1221-1233. [PMID: 20678672 DOI: 10.1016/j.clinthera.2010.07.002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 2.0] [Reference Citation Analysis]
16 Akiho H, Ihara E, Motomura Y, Nakamura K. Cytokine-induced alterations of gastrointestinal motility in gastrointestinal disorders. World J Gastrointest Pathophysiol 2011; 2(5): 72-81 [PMID: 22013552 DOI: 10.4291/wjgp.v2.i5.72] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 55] [Article Influence: 5.6] [Reference Citation Analysis]
17 Hagsäter SM, Lisinski A, Eriksson E. 5-HT6 receptor antagonism reduces defecation in rat: A potential treatment strategy for irritable bowel syndrome with diarrhea. European Journal of Pharmacology 2019;864:172718. [DOI: 10.1016/j.ejphar.2019.172718] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]